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A targetable acid-responsive micellar system for
signal activation based high performance surgical
resolution of tumors†
Xuanjun Wu,a Yunpeng Tian,a Mingzhu Yu,a Jiahuai Hanb and Shoufa Han*a
Tumor-reporting probes are valuable to guide surgical resection of tumor foci elusive to visual inspection.
As tumors display distinct arrays of lectins, we herein report the construction and screening of a panel of
glycan-displaying smart micelles for tumor illumination in mice. These micelles consist of cores of rhod-
amine-sultam (RST) responsive to lysosomal acidity and a corona of poly[styrene-alter-(maleic acid)] gly-
cosylated with D-glucosamine, D-mannosamine or D-galactosamine. These nanoscale micelles are
nonfluorescent extracellularly and become luminescent within acidic lysosomes, enabling optical tracking
of tumor endocytosis of the micelles. In vivo screening revealed high-efficiency uptake and fluorescence
activation of galactosylated micelles (RST@P-Gal) by subcutaneous tumor and disseminated liver tumor
foci with diameters of 0.1–10 mm, which is significantly below minimal residual cancer (a minimum of
1 cm clearance). This system is readily adapted to illuminate different tumors by expanding the diversity of
glycans on the shell. Given the robustness and high performance of this system, lectin-targeted respon-
sive micelles are attractive for diagnosis or surgical ablation of tumors.
Introduction
With the global prevalence of cancer, methods that could
improve the outcome of available modalities for cancer treat-
ment are of clinical significance. Surgical resection is widely
used in treatment of tumors where the limited visibility of
tumor foci under visual inspection often results in incomplete
removal and hence tumor relapse. As such, luminescent
probes that could direct surgeons to elusive tumor foci are of
significant value.1 The utility of fluorescence guided oncogenic
surgery has been demonstrated by a number of clinical
methods, e.g. imaging of epithelial ovarian cancer with fluo-
rescein-isothiocyanate tagged folate.2 Conventional dyes lack
the ability to recognize tumors and thus are often integrated
with tumor-targetable biochemical entities such as mono-
clonal antibody, folate, and fluorogenic substrates specific for
tumoral enzymes, etc.2,3 Apart from selectivity, optical systems
that could be activated to the fluorescence-on states inside
tumors while being nonfluorescent in off-target settings are
advantageous owing to the intrinsic low-background signals
and improved ability to discern tumors.4 In this regard, optical
probes responsive to lysosomal pH of tumors are attractive for
imaging viable cancer cells.3c,4g
Cell surface protein–glycan interactions mediated a wealth
of biological events ranging from cell trafficking, endocytosis
to cancer metathesis, etc.5 Glycan-binding proteins, known as
lectins, are often expressed in patterns unique to defined cell
lines or tissues, and thus are attractive targets for glycan
mediated delivery of therapeutics.6 To date, the use of glyco-
probes with responsive properties has been largely unexplored
for surgical tumor detection. To develop targetable systems for
intraoperative tumor imaging, we report the construction and
screening of a group of carbohydrate-displaying polymeric
micelles with lysosome-activatable fluorescence in subcu-
taneous tumor and liver tumor models. The probes consist of
hydrophilic shells of glycosylated poly[styrene-alter-(maleic
acid)] and hydrophobic cores of rhodamine-sultam (RST)
which isomerizes into highly fluorescent species upon intern-
alization into lysosomes (Fig. 1). Studies in tumor-bearing
mice reveal that lectin-targeted glyco-micelles possess features
advantageous for low-background detection of disseminated
tumor foci during oncogenic surgery.
†Electronic supplementary information (ESI) available: Experimental pro-
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Results and discussion
Endocytic lectins are often expressed in a tissue- or cell type-
dependent manner.7 For instance, mannose receptors are rich
in macrophages8 whereas asialoglycoprotein receptors
(ASGPR) that bind terminal galactose on proteins are abun-
dantly expressed on the plasma membrane of hepatocytes.9
Much effort has been devoted to the use of glycan-bearing
vectors for delivery of therapeutics by targeting cell surface
lectins such as ASPGR,10 mannose receptors,11 Siglecs, etc.12
In contrast, there is a lack of effort on the use of glyco-probes
for fluorescence-guided tumor detection. As mentioned above,
optical probes that are emissive in tumor lysosomes while
being nonfluorescent at extralysosomal settings are appealing
tools for low-background tumor imaging. In this context, we
set out to examine the efficacy of a panel of lysosome-activat-
able glycan-presenting micelles to illuminate tumors in mice
models (Fig. 1).
Rhodamine-sultam for imaging of lysosomal acidity
Albeit widely used for bioimaging owing to their distinguished
photophysical properties such as intensive fluorescence and
bioorthogonal fluorescence spectra, rhodamines are pH insen-
sitive. As such, nonfluorescent rhodamine-(deoxy)lactams fea-
turing intra-molecular (deoxy)lactams have been developed for
lysosome imaging in live cells where the acidic pH of the lyso-
somal lumen triggered fluorogenic opening of the spiro-
(deoxy)lactams to give fluorescent rhodamine species
(Fig. 2A).13 However, rhodamine-lactams typically exhibit low
levels of fluorescence emission at lysosomal pH whereas the
use of rhodamine-deoxylactam, albeit sensitive to acidic pH, is
compromised by its cross-reactivity to biological aldehydes.14
Sulfonamide is significantly more acidic (pKa ∼ 10) than
amide (pKa ∼ 20–23). Because sulfonamide is a better leaving
group than the amide moiety, rhodamine-sultam (RST) is
anticipated to be more vulnerable to the opening of intramole-
cular sultam as compared to rhodamine-lactams (Fig. 2B) and
thus displays enhanced pH sensitivity. RST was prepared from
coupling of sulforhodamine with ethylenediamine to give rho-
damine-sulfonamide which spontaneously self-rearranges to
yield the nonfluorescent RST (ESI, Scheme S1†). Analysis of
RST fluorescence emission in buffers of various pH shows that
RST is 8–10 fold brighter than N-(rhodamine B)-lactam-
ethylenediamine (RLT), the structural analog of RST, in the
range of pH 4.0–6.5 which fully matches the lysosomal pH
window (pH 6.5–4.0) (Fig. 2C). The UV-vis absorption spectrum
and fluorescence spectra of RST in acidic media are almost
identical to that of sulfo-rhodamine (ESI, Fig. S1–S3†), validat-
ing proton mediated isomerization of RST into the highly fluo-
rescent rhodamine-sulfoamide as proposed in Fig. 2B.
With the superior pH sensitivity, RST was evaluated for its
capability to fluoresce in lysosomes. Raw 264.7 macrophages
and human hepatocellular carcinoma QGY-7701 cells were
respectively co-stained with RST and LysoTracker Green
DND-26 (referred to as Lysotracker green). Confocal
microscopy analysis shows that strong rhodamine fluorescence
were clearly present within cells and colocalizes with Lyso-
tracker green which is a lysosome specific marker (Fig. 3). The
colocalization validates that RST becomes fluorescent within
lysosomes. Next, Raw 264.7 cells and QGY-7701 cells pretreated
with Bafilomycin A1 (BFA) were co-stained with RST and
Fig. 1 Tumor imaging with lectin-targeted acid responsive micelles. (A)
Illustration of tumor illumination with glyco-micelles by virtue of
enhanced permeability and retention (EPR) effects of tumor vasculature,
tumor surface lectin mediated endocytosis, and signal activation of
internalized micelles within lysosomes. (B) Proton mediated fluo-
rescence activation of RST moieties of the micellar system.
Fig. 2 Acidic pH mediated fluorogenic opening of the sultam of RST
and the lactam of RLT. RLT (A) and RST (B) were respectively spiked into
sodium phosphate buffer (100 mM) of various pH values to a concen-
tration of 1 μM. The fluorescence emission of the resultant solutions was
recorded using λex@560 nm. (C) pH dependent fluorescence emission
of RST. (D) pH profiles of RST (in red) and RLT (in dark) were plotted by
fluorescence emission intensities@590 nm over buffer pH.
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Lysotracker green. BFA inhibits the proton pumping activity of
the ATP–H1 pump and thus effectively alkalinizes the lyso-
somal pH.15 It is shown that the intralysosomal fluorescence
of RST largely disappeared in BFA-treated cells (Fig. 4), proving
that RST is activated by lysosomal acidity to give fluorescent
rhodamine-sulfonamide.
Construction and characterization of pH responsive micelles
Poly[styrene-alter-(maleic acid)] is biocompatible as its conju-
gate with neocarzinostatin has been marketed in Japan for
treatment of primary hepatoma and secondary liver tumor.16
We have previously shown that polyanionic poly[styrene-alter-
(maleic acid)] derivatives are potent microbicides against
HIV-1 infection17 and exhibit low levels of nonspecific binding
to mammalian cells owing to Coulombic repulsion with the
negatively charged host cell surfaces.18 Given these
advantageous biomedical properties, poly[styrene-alt-(maleic
acid)] was used as the carrier of RST and targeting glycans for
fluorescence guided tumor detection.
Poly[styrene-alter-(maleic anhydride)]40 was partially ami-
dated with RST and then respectively amidated with D-galacto-
samine (Gal), D-mannosamine (Man), D-glucosamine (Glu) in
dimethylformamide (ESI†). The resulting solutions were
treated with an aqueous solution of sodium carbonate to
hydrolyze unreacted anhydride moieties, extensively dialyzed
in distilled water, and then sonicated to afford poly[styrene-
alter-(maleic acid-RST)] decorated with Man, Gal, or Glu,
which are correspondingly designated as RST@P-Man,
RST@P-Gal, and RST@P-Glu. In parallel, poly[styrene-alter-
(maleic acid-RST)] was prepared and used as the glycan-free
control (designated as RST@P). Dynamic light scattering analy-
sis shows that the hydrodynamic diameters are 110.2 nm,
86.9 nm, 139.4 nm and 59.4 nm for RST@P, RST@P-Glu,
RST@P-Gal, and RST@P-Man (Fig. 5), confirming that the as-
prepared polymers self-assembled into nanoscaled micelles
upon sonication in aqueous solutions. Zeta potentials of these
micelles are in the range of −40 mV to −50 mV (ESI, Fig. S4†),
which is consistent with the anionic nature of the micelles.
The dense surface charges are beneficial for the colloidal stabi-
lity of the micelles.
The micelles were respectively spiked into buffers of various
pH (4–9) to probe their pH responsiveness. Analysis of the
solutions by UV-vis spectroscopy showed that these RST-
appended micelles display strong absorbance peaked at
560 nm under acidic pH (ESI, Fig. S1†), suggesting the for-
mation of deep colored rhodamine-sulfoamide. The micelles
exhibit fluorescence emission which is centered at 590 nm and
intensifies as the buffer pH decreases (ESI, Fig. S2†). The
levels of RST conjugated in these micelles are similar as deter-
mined by their UV-vis absorbance at acidic pH (Fig. 6A; ESI,
Fig. S5†). In contrast, the glyco-micelles are more emissive that
RST@P under acidic conditions (Fig. 6B), suggesting the ben-
eficial impacts of the glycan moieties on fluorescence emis-
sion of conjugated RST. RST displays 10-fold fluorescence
enhancement in pH 4.5 over pH 9.0 whereas RST@P-Gal exhi-
bits 4-fold enhancement (Fig. 6B). The dampened fluorescence
emission is likely due to the interference of the polymeric
Fig. 3 Selective staining of lysosomes with RST. Raw 264.7 cells and
QGY-7701 cells prestained with DAPI (1 μM) were respectively cultured
in DMEM containing RST (1 μM) for 30 min, and then stained with Lyso-
tracker green (1 μM) for 20 min. The nuclei stained with DAPI were
shown in blue. Merging of RST fluorescence (shown in red) and that of
Lysotracker green (in green) revealed colocalization, indicated by the
yellow areas. Bars, 5 μm.
Fig. 4 Lysosomal pH triggered fluorescence activation of RST. Raw
264.7 cells (A) and QGY-7701 cells (B) precultured in the absence or
presence of BFA (50 nM) were first cultured in DMEM with RST (1 μM) for
30 min and then stained with Lysotracker green (1 μM) in DMEM for
20 min. The cells were visualized by confocal fluorescence microscopy.
Overlay of the RST signal (in red) with Lysotracker green (in green)
revealed colocalization, indicated by the yellow areas. Bars, 5 μm.
Fig. 5 Diameter sizes of the nanoscaled micelles as measured by
dynamic light scattering.
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carrier on the fluorescence properties of pendent RST moieties
under the assay conditions. Collectively, these titrations
confirm that RST within micelles is poised to proton triggered
fluorogenic opening of the sultam at acidic settings.
Lysosomal acidity mediated fluorescence activation of the
micelles
Lysosomes are the major acidic compartments within cells
and the lysosomal pH is critical for a wealth of biological
activities such as autophagy, endocytosis and cancer meta-
thesis. Optical probes that could be selectively activated in
lysosome are powerful tools for low-background cancer
imaging.3c,4a To probe the feasibility of lysosome mediated
fluorescence activation, QGY-7701 cells and Raw 264.7 cells
were respectively cultured with each of the micelles in medium
supplemented with Lysotracker green. As shown in Fig. 7,
rhodamine fluorescence is clearly present within micelle-
treated cells where it colocalizes with Lysotracker green,
proving that these micelles become fluorescent upon internal-
ization into lysosomes. To ascertain the correlation of the
intralysosomal fluorescence with lysosomal pH, we acquired
the signals of the micelles in cells pretreated with BFA. The
intracellular fluorescence largely vanished in BFA-treated cells
(Fig. 8), confirming lysosomal acidity mediated fluorescence
activation of the internalized micelles.
Lectin-mediated cellular uptake of the glyco-micelles
Lectins are abundantly expressed on cancer cells and the ele-
vated levels of cell surface lectins are often associated with
tumor clones with higher metastatic potentials.19 Despite a few
examples, e.g. galactose receptors identified on certain
cancers,20 information is lacking on the identity and density of
functional lectins on various cancers. In addition, cancer cells
express higher levels of glucose transporters than normal cells,21
which underlies the use of glucose derivatives for imaging and
treatment of cancers.22 Given the heterogeneity of cell types in
tumor foci, the micelles with multivalent monosaccharides of
Gal, Man or Glu are directly screened for their efficacy to target
tumors in vivo by tumoral lectins or glucose transporters.
As a proof of concept, Raw 264.7 cells and QGY-7701 cells
were treated with the micelles to probe the influence of
glycans on the cellular uptake of these micelles. No obvious
fluorescence was identified in cells or culture medium right
after addition of these micelles which is consistent with the
nonfluorescent nature of the micelles under extracellular con-
ditions. Flow cytometry analysis of the cells at 60 min post-
incubation showed that RST@P-Man and RST@P-Gal were
effectively internalized into both cell lines as determined by
the mean channel fluorescence (MF) which is an indicator of
the intracellular fluorescence intensity. RST@P-Glu entered
cells with efficiency 50% that of RST@P-Man (Fig. 9) whereas
the glycan-free RST@P exhibits low levels of cell uptake with
MF values roughly 10–20% that of RST@P-Man or RST@P-Gal.
Although the lectins targeted by these distinct glyco-micelles
remain obscure at this stage, e.g. in the cross-reactivity of Raw
264.7 cells to RST@P-Gal, the preferred cellular internalization
of glyco-micelles over RST@P clearly supports the critical roles
of glycans on the active uptake of the micelles by lectin-expres-
sing mammalian cells.
Besides high-efficiency cellular accumulation, retention of
the internalized imaging probes within lysosomes is another
critical factor for practical tumor detection. QGY-7701 cells
and Raw 264.7 cells pre-cultured with RST or each of the
Fig. 6 pH profiles of the micelles. The micelles were respectively
spiked into sodium phosphate buffer (100 mM) of various pH (3.9–8.9)
to a final concentration of 50 μg ml−1 (A) or 10 μg ml−1 (B). The solutions
were analyzed by UV-vis spectrometry and fluorometry. The titration
profiles were plotted using the absorbance at 560 nm (A) or the fluo-
rescence emission (B) of the solutions over buffer pH (λem@590 nm;
λex@560 nm).
Fig. 7 Illumination of lysosomes with the micelles. Raw 264.7 cells (A)
and QGY-7701 cells (B) prestained with DAPI (1 μM) were respectively
cultured for 30 min in DMEM supplemented with the indicated micelles
(10 μg ml−1), and then stained with Lysotracker green (1 μM) in DMEM for
20 min. Merging of the intracellular RST fluorescence shown in red and
that of Lysotracker green shown in green demonstrates colocalization
where yellow was observed. Bars, 10 μm.
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micelles were incubated in micelle-free culture medium. Cells
were visualized by fluorescence microscopy to probe the
amounts of micelles remained in lysosomes over time. It was
shown that RST fluorescence within these cell populations
remains largely unaffected up to 48 h (Fig. S7, S8, ESI†),
suggesting superior lysosomal retention of RST and the RST-
functionalized micelles.
Illumination of subcutaneous tumors with RST@P-Man and
RST@P-Gal
On the basis of glycan-facilitated cellular endocytosis and fluo-
rescence activation of the internalized micelles within lyso-
somes, we assessed whether these probes could target
subcutaneous tumors in mice. H22 hepatocellular carcinoma
cells were injected subcutaneously into the flank of ICR mice.
Within 5–10 days after inoculation, the micelles were respect-
ively injected into the bloodstreams of tumor-bearing ICR
mice via the tail vein. The mice were sacrificed 17 h post-injec-
tion and the biodistribution was assessed by measuring fluo-
rescence emission in the dissected organs.
To our delight, the most intense signals were observed in
tumors of mice treated with RST@P-Gal or RST@P-Man, and
Fig. 8 Lysosomal acidity mediated fluorescence activation of the micelles. Raw 264.7 cells (A) and QGY-7701 cells (B) pretreated with or without
BFA were respectively treated with RST@P (10 μg ml−1), RST@P-Glu (10 μg ml−1), RST@P-Gal (1 μg ml−1) or RST@P-Man (1 μg ml−1) in DMEM for
30 min and then stained with Lysotracker green (1 μM) in DMEM for 20 min. The intracellular fluorescence of the micelles within cells was probed by
confocal fluorescence microscopy. Merging of RST fluorescence shown in red and that of Lysotracker green shown in green demonstrate colocali-
zation, indicated by the yellow areas. Bars, 10 μm.
Fig. 9 Flow cytometric analysis on differential cellular uptake of the
micelles. QGY-7701 cells (A) and Raw 264.7 cells (B) were respectively
cultured in DMEM spiked with or without the micelles (10 μg ml−1) for
60 min. The cells were washed with PBS and then analyzed by flow
cytometry. The cell populations were gated under identical conditions
and the intracellular fluorescence (λem@PE channel) was collected
using λex@488 nm. The mean channel fluorescence (MF) values indicat-
ing the intracellular fluorescence intensity were measured and included.
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surprisingly, no obvious uptake of RST@P-Glu was seen in the
tumor (Fig. 10). Consistent with the previous report,23 accumu-
lation of RST@P was observed in the excised tumor (Fig. 10).
The lack of fluorescence in the organs and the tumor from
PBS-treated mice (Fig. 10) validates that the observed tumor-
associated fluorescence originates from internalized micelles
in mice. The preferred tumoral uptake of RST@P over
RST@P-Glu reveals the limitations to predict in vivo perform-
ance of probes on the basis of their in vitro properties,
e.g. elevated cellular accumulation of RST@P-Glu over RST@P
(Fig. 9). The high tumor to background fluorescence ratios dis-
played by RST@P-Gal or RST@P-Man (Fig. 10B) validate the
feasibility to illuminate tumors in vivo with responsive glyco-
micelles which undergo fluorescence activation upon tumor
lectin-mediated endocytosis into the lysosomes.
To probe temporal retention of the micelles in tumors, a
cohort of mice with subcutaneous tumors were intravenously
administered with these micelles and then sacrificed at 4, 10,
17 or 39 h following injection. RST fluorescence in the tumors
and other organs was determined ex vivo. As shown in Fig. S9
(ESI†), high-efficiency accumulation of RST@P-Man and
RST@P-Gal were observed in tumors at 17 h post-injection,
which decreased dramatically to background levels by 39 h
post-injection. Concurrently, the liver-associated fluorescence
in mice treated with both glyco-micelles significantly
decreased (Fig. S9, ESI†), suggesting that the liver is the major
excretion organ of these polymeric agents.
High resolution imaging of liver tumor foci with RST@P-Gal
Liver cancer, constituted mostly by hepatocellular carcinoma,
is one of the most common and lethal malignancies with over
600 000 new cases diagnosed annually and roughly equal
number of deaths.24 Albeit offering limited chances to cure,
cytoreductive surgery corroborated chemotherapy remains the
major modality for treatment of liver cancer. Hence,
approaches that could assist complete surgical removal of
cancer cells will in principle lead to cancer cure. To ascertain
whether the glyco-micelles could be used to discern tumor foci
in liver, ICR mice with H22 hepatocellular carcinoma in the
liver were intravenously administered with the micelles. At
15 h after injection, the liver and other healthy organs were
excised and probed ex vivo. No fluorescence is observed in
tumors excised from mice treated with RST@P-Man,
RST@P-Glu or RST@P (Fig. 11). In sharp contrast, intensive
fluorescence is observed in disseminated tumor foci with
diameters in the range of 0.1–5 mm in the liver from
RST@P-Gal-treated mice (Fig. 11B).
Symptoms of human hepatocellular carcinoma often occur
till the tumor reaches 4–8 cm in diameter.25 As incomplete
surgical removal of tumor foci often leads to treatment failure,
a minimum of 1 cm clearance, defined as minimal residual
disease, was aimed by most surgeons during resection of
many cancers.26 As shown in Fig. 11, the sizes of tumor foci
unambiguously differentiated by RST@P-Gal (0.1–5 mm) are
Fig. 10 High-efficiency illumination of subcutaneous tumors with
RST@P-Gal and RST@P-Man. ICR mice with subcutaneous tumors were
intravenously injected with each of the micelles (10 mg kg−1) or PBS via
the tail vein and then sacrificed 17 h post-injection. The tumors and
representative organs were dissected and imaged by ex vivo fluo-
rescence analysis (A). The bar graph shows the tissue distributions of RST
fluorescence (B). The organs were shown in the following sequence: liver
(1), tumor (2), lung (3), heart (4), kidney (5) and spleen (6).
Fig. 11 High resolution illumination of tumor foci (white arrows) in liver
with RST@P-Gal. ICR mice with liver tumors were intravenously injected
with PBS or each of the micelles (10 mg kg−1) via the tail vein, sacrificed
15 h post-injection. The representative organs were excised and visuali-
zed ex vivo by fluorescence analysis (A). Enlarged fluorescence image of
the liver from RST@P-Gal treated mice was shown for clarity. Bar: 1 cm.
(B) The bar graph shows the fluorescence intensity of RST@P-Gal in
tumor foci vs. surrounding liver tissue and other organs. The organs are
arrayed in the following sequence: liver (1), lung (2), heart (3), kidney (4)
and spleen (5).
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significantly below the current limit of minimal residual
cancer (tumor deposit < 1 cm). Given the facts that hepatocytes
efficiently capture nanoscaled materials or galactose-present-
ing proteins,27 the capability of RST@P-Gal to illuminate
tumor foci at sub-mm levels and the stringent selectivity for
tumor over neighboring liver tissue highlight its clinical poten-
tials to improve surgical resection of tumor foci that are other-
wise elusive to visual inspection during surgery. Galactose-
containing proteins have been documented to bind a number
of different tumors, suggesting the presence of galactose recep-
tors in these tumors.20a In addition, nanomaterials have been
widely used for tumor imaging by enhanced permeability and
retention (EPR) effects.28 The tumor-specific accumulation of
RST@P-Gal is likely due to a combination of passive targeting
via EPR effects and subsequent active targeting by tumor
surface lectin mediated absorption of local micelles.
Cytotoxicity of the micelles
The cytotoxicity of the micelles was evaluated in QGY-7701
cells and Raw 264.7 cells by the Trypan Blue exclusion test. No
detrimental effects on cell viability were observed at doses up
to 100 μg ml−1 after incubation up to 48 h (Fig. 12), suggesting
that these polymers are of low cell toxicity. To investigate the
systemic toxicity, RST@P-Gal was respectively injected via the
tail vein at doses up to 100 mg kg−1 in healthy mice, which is
10 times higher than the amount employed for tumor imaging.
The mice were regularly monitored for adverse effects following
injections. No signs of toxicity, pain or fatigue were observed on
the mice receiving the micelles up to 7 days following injection.
Ex vivo analysis revealed low levels of fluorescence in the organs
excised from the mice (ESI, Fig. S10†), suggesting that these
micelles might have been cleared from the body. The biocom-
patibility of poly[styrene-alter-(maleic acid)] has been demon-
strated by its conjugate marketed for treatment of liver
tumors.16 Consistently, these data indicate that these polymeric
micelles are of low cellular and systemic toxicity.
Conclusions
We demonstrate the use of acid-responsive glyco-micelles for
targeted tumor imaging in mice models. High-performance in
vivo illumination of disseminated liver tumors and
subcutaneous tumors was achieved with RST@P-Gal featuring
lysosome activatable rhodamine-sultam (RST). RST is non-
fluorescent extracellularly and is poised to lysosomal pH
mediated fluorescence activation, allowing optical tracking of
glyco-micelles within viable cancer cells. With the high resolu-
tion to discern tumor foci, intense intratumoral fluorescence
and low background signals, RST@P-Gal is of clinical utility
for fluorescence-guided surgical ablation of liver tumors. As
different tumors often display distinct lectins, this system is
readily adaptable to illuminate different tumors by incorpo-
ration of appropriate glycans on the corona. The lectin-
targeted multifunctional system offers an effective and facile
approach for in vivo optical tracking of tumors and thus would
be of broad potential for cancer diagnosis and surgery.
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